5 innovadores medicamentos chinos, incluyendo inhibidores de:
🧬 KRAS G12C
🧬 EGFR de tercera generación
🧬 EGFR exon 20

#Fulzerasib #Sunvozertinib #Limertinib #Glecirasib #Garsorasib #Cáncer #Oncología #TerapiaDirigida #InnovaciónMédica #KRAS
#KRASG12C #EGFR #EGFRexon20 #DengYueMedicinasEnHongKong

🎯 4 dianas clave.
🧬 Tratamiento de precisión.
🌍 Impacto global.

📎 Más información: dengyuepharma.com
📧 info@dengyuemed.com
#CáncerDePulmón #CáncerDePulmónNoMicrocítico #NSCLC #Oncología #OncologíaClínica #SaludGlobal #EGFR #ALK #PD1 #PDL1 #KRAS #KRASG12C #DengYueMedicinasEnHongKong

💊 Glecirasib Citrate Tablets—now approved in China!
🎯 Targets KRAS G12C–mutated advanced NSCLC

📎 Learn more: dengyuemed.com/product/airu...
📧 info@dengyuemed.com

#GlecirasibCitrateTablets #Allist #KRASG12C #KRAS #KRASInhibitor #NSCLC #LungCancerTreatment
#HongKongDengYueMedicine

China NMPA Grants Conditional Approval for Garsorasib Tablets

📩 info@dengyuemed.com
🔗https://dengyuemed.com

#ChinaNMPA #DrugApproval #Garsorasib #NSCLC #KRASG12C #InnovativeDrug #ChiataiTianqing #LungCancer

Sage Journals: Discover world-class research Subscription and open access journals from Sage, the world's leading independent academic publisher.

This review outlines current therapies and future directions for KRAS G12C-mutant NSCLC
• Targeted inhibitors: sotorasib, adagrasib
• Immunotherapy combos: checkpoint inhibitors + KRAS blockade
• Dual ICI strategies under exploration
Read more: buff.ly/KdmExKt
#CancerResearch #NSCLC #KRASG12C

At #ASCO25 Dr. Fontana presents:
KRAS G12C: From First to Next Gen
• Early trials: safe KRAS G12C + anti-EGFR ± chemo
• No unexpected toxicities
• Promising, but not practice-changing
• FDA-approved:
 – Sotorasib + panitumumab
 – Adagrasib + cetuximab
#GIcancer #KRASG12C

New Biomarker May Guide Best Use of KRAS Inhibitors in Lung Cancer - OncoDaily New Biomarker May Guide Best Use of KRAS Inhibitors in Lung Cancer / Abraham Anderson, Adrian Sacher, Adrianus Johannes de Langen, Alessandra Curioni

New Biomarker May Guide Best Use of KRAS Inhibitors in Lung Cancer
@mdanderson.bsky.social

oncodaily.com/insight/kras...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #KRASInhibitors #KRASG12C #Biomarker #LungCancer #NSCLC #TTF-1 #Sotorasib #CodeBreaK200

Thanks my #coinvestigators for opportunity to present data of #D3S_001, a novel #KRASG12C inhibitor in #G12Ci pre-treated #NSCLC at @theaacr.bsky.social #AACR25. Strong & rapid #targetengagement confer superior #efficacy c.f. 1st generation G12Ci.

✔️ORR 30%; DCR 80% in KRASG12Ci pre-treated popn.

Featured today by @MSKLibrary: Lung adenocarcinomas with mucinous histology: clinical, genomic, and immune microenvironment characterization and outcomes to immunotherapy-based treatments and KRASG12C inhibitors

dx.doi.org/10.1016/j.an...

#LungCancer #Adenocarcinoma #MucinousHistology #KRASG12C

Featured today by @MSKLibrary: Pooled safety analysis and management of sotorasib-related adverse events in KRAS G12C-mutated advanced non-small cell lung cancer

#Sotorasib #KRASG12C #LungCancer #NSCLC #Oncology #CancerResearch #TargetedTherapy #CancerTreatment

academic.oup.com/oncolo/artic...

Genomic landscape of clinically acquired resistance alterations in patients treated with KRASG12C inhibitors Mutant-selective inhibitors of KRASG12C (KRASG12Ci) have demonstrated efficacy in KRASG12C cancers. However, resistance invariably develops, resulting in short-lived responses. We aimed to define the ...

⚠️ #CorcoranLab reports "Genomic landscape of clinically acquired resistance alterations in patients treated with #KRASG12C inhibitors", a work led by our brilliant Austrian postdoc Jakob Riedl! @mgbresearch.bsky.social @fwf-at.bsky.social @harvardmed.bsky.social @oncoalert.bsky.social #crcsm #lcsm

FDA Greenlights Amgen’s Dual Therapy for KRAS G12C-Mutated Colorectal Cancer On January 16, 2025, the U.S.

www.linkedin.com/pulse/fda-gr...

FDA Greenlights Amgen’s Dual Therapy for KRAS G12C-Mutated Colorectal Cancer

kstrategyand.com/pharma-news

#FDAApproval #Amgen #Sotorasib #Panitumumab #ColorectalCancer #KRASG12C #CancerCare #HealthBreakthrough #Humanteconomy #Humantec #KStrategyand

S11 Ep38: Pancreatic Cancer Research Surfaces Treatment Developments and Challenges: With John Strickler, MD OncLive® On Air · Episode

INVESTIGATIVE UPDATE: Spotify link confirms lack of text transcript availability, listening confirms that #KRASG12C is quite rare in #pancsm but there are exciting new agents targeting other KRAS variants in trials: open.spotify.com/episode/5EHF...